Scarica l'app Stockscreener
1.97
1.03%
0.02
Dopo l'orario di chiusura:
1.95
-0.02
-1.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.95
Aprire:
$1.97
Volume 24 ore:
10.84M
Relative Volume:
0.89
Capitalizzazione di mercato:
$712.85M
Reddito:
$241.53M
Utile/perdita netta:
$-389.92M
Rapporto P/E:
-1.6016
EPS:
-1.23
Flusso di cassa netto:
$-323.54M
1 W Prestazione:
-12.44%
1M Prestazione:
-9.22%
6M Prestazione:
-45.13%
1 anno Prestazione:
-81.13%
Intervallo 1D:
$1.94
$2.00
Intervallo di 1 settimana:
$1.93
$2.35
Portata 52W:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Confronta IOVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
1.97 | 705.62M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
How Iovance Biotherapeutics Inc. stock trades during market volatilityQuarterly Portfolio Review & Weekly Hot Stock Watchlists - newser.com
HC Wainwright Issues Negative Forecast for IOVA Earnings - MarketBeat
Will Iovance Biotherapeutics Inc. stock beat EPS estimates2025 Institutional Moves & Safe Swing Trade Setup Alerts - newser.com
How big funds are accumulating Iovance Biotherapeutics Inc. (2LB) stockQuarterly Market Summary & Low Risk High Reward Trade Ideas - newser.com
Published on: 2025-11-01 04:05:22 - newser.com
Can Iovance Biotherapeutics Inc. stock deliver strong Q4 earnings2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
Using portfolio simulators with Iovance Biotherapeutics Inc. includedWeekly Investment Recap & Advanced Technical Signal Analysis - newser.com
Does Iovance Biotherapeutics Inc. stock trade at a discount to peersMarket Trend Review & Community Shared Stock Ideas - newser.com
Why Iovance Biotherapeutics Inc. stock appeals to analystsShort Setup & Free Technical Pattern Based Buy Signals - newser.com
Is it time to cut losses on Iovance Biotherapeutics Inc.CEO Change & Short-Term Trading Opportunity Alerts - newser.com
Is Iovance Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 News Drivers & AI Powered Market Entry Ideas - newser.com
What Wall Street predicts for Iovance Biotherapeutics Inc. stock price2025 Valuation Update & Stepwise Entry and Exit Trade Signals - newser.com
Is Iovance Biotherapeutics Inc. stock poised for growth2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
Iovance Biotherapeutics (IOVA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Using RSI to spot recovery in Iovance Biotherapeutics Inc.Earnings Trend Report & Growth Focused Stock Reports - newser.com
Why Iovance Biotherapeutics Inc. stock is favored by top institutionsPortfolio Return Report & Consistent Income Trade Ideas - newser.com
Will Iovance Biotherapeutics Inc. stock see PE expansionJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Published on: 2025-10-31 03:11:42 - newser.com
Published on: 2025-10-31 02:59:28 - newser.com
How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stockTrend Reversal & Verified Technical Signals - newser.com
Can trapped investors hope for a rebound in Iovance Biotherapeutics Inc.Quarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Will Iovance Biotherapeutics Inc. stock gain from lower inflationJuly 2025 Highlights & Fast Moving Market Watchlists - newser.com
What insider trading reveals about Iovance Biotherapeutics Inc. stockJuly 2025 EndofMonth & AI Powered Trade Plan Recommendations - newser.com
Automated trading signals detected on Iovance Biotherapeutics Inc.Market Movement Recap & Daily Chart Pattern Signal Reports - newser.com
Why analysts upgrade Iovance Biotherapeutics Inc. stock2025 Trade Ideas & Stepwise Trade Signal Implementation - newser.com
What MACD trends signal for Iovance Biotherapeutics Inc. (2LB) stockTrade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 6.2% After Analyst Downgrade - MarketBeat
Iovance Biotherapeutics Stock Hits Day Low of $2 Amid Price Pressure - Markets Mojo
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $9.00 Price Target at HC Wainwright - MarketBeat
Iovance Biotherapeutics, Inc. Securities Lawsuit Investigation - Claim Depot
Why Iovance Biotherapeutics Inc. (2LB) stock fits value portfoliosDay Trade & Smart Allocation Stock Reports - newser.com
Published on: 2025-10-30 00:18:19 - newser.com
IOVA: Analyst Lowers Price Target to $9.00 While Maintaining 'Bu - GuruFocus
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Valuation Update: Can Iovance Biotherapeutics Inc. stock deliver consistent earnings growthJuly 2025 Gainers & Long Hold Capital Preservation Plans - Fundação Cultural do Pará
Can Iovance Biotherapeutics Inc. stock outperform in 2025 bull market2025 Market WrapUp & Community Consensus Picks - Fundação Cultural do Pará
Can Iovance Biotherapeutics Inc. stock surprise with earnings upsideJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - Fundação Cultural do Pará
Can Iovance Biotherapeutics Inc. stock deliver consistent earnings growth2025 Volume Leaders & AI Powered Market Trend Analysis - Fundação Cultural do Pará
Can Iovance Biotherapeutics Inc. stock beat market expectations this quarterEarnings Risk Summary & Real-Time Volume Triggers - Fundação Cultural do Pará
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Iovance Biotherapeutics Inc Azioni (IOVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
5,470 |
0 |
215,324 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,697 |
0 |
111,857 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,306 |
0 |
105,939 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Jun 05 '25 |
Buy |
1.84 |
30,000 |
55,200 |
30,000 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
| Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
| Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):